Congress sets its sights on bringing down IPAB

Share this article:
Sen. John Cornyn (R-TX)
Sen. John Cornyn (R-TX)

Congressional Republicans—and a few Democrats—are pressing the attack on the Independent Payment Advisory Board for Medicare, a part of the Affordable Care Act opposed by both PhRMA and the AMA.

In February, the House Energy and Commerce Health Subcommittee voted 17-5 to repeal IPAB, the primary cost-cutting mechanism of the Affordable Care Act. The panel's 15 Republicans were joined by two Democrats representing pharmacentric districts. A similar bill, authored by Sen. John Cornyn (R-TX), is bottled up in the Senate.

In a post to The Hill's Congress Blog, the author of the House bill, Tennessee Republican Phil Roe, called IPAB a “dangerous rationing board.”

Starting in 2015, IPAB will be able to issue binding recommendations for cutting Medicare spending that will take effect unless Congress makes alternate cuts.

PhRMA and the AMA oppose the board. PhRMA SVP Matt Bennett says it “could enact sweeping Medicare changes without Congress' oversight… We believe IPAB will result in access problems for Medicare beneficiaries.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets